Normal liver enzymes no reason to withhold antiviral therapy for chronic HCV
At Digestive Disease Week in New Orleans, Steve Flamm, MD, associate professor of medicine and medical director of liver transplantation, Northwestern University, Chicago, Ill, presented study findings indicating that patients with chronic hepatitis C virus (HCV) infection and persistently normal liver enzymes derive as much benefit from pegylated interferon-alfa 2b plus ribavirin therapy as do patients with elevations in serum alanine aminotransferase (ALT). According to Dr Flamm, lead investigator for the study, "... a fraction of patients with normal liver enzymes do have aggressive liver disease on liver biopsy despite their liver tests being normal."
Jenny Goins, interim head of the National Alliance of Healthcare Purchaser Coalitions, says employers need the same visibility into medical benefits that a new Department of Labor rule gives them into PBM compensation.
People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.
Adding Sunharbo (asundexian), a first-in-class factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.